Metacurum Biotech is developing drugs targeting the oncogenic TGFbeta pathway. The first indication is prostate cancer. The rationale for development in other solid tumors is also great. We have developed a very specific mAb that inhibits oncogenic cleavage of the TGFbRI. Research is being conducted with founder Prof Marene Landström, Umeå University and collaborators.
Company Details
- Founded
- -
- Address
- Tvistevägen 48c, Umeå,907 36,sweden
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.metacurum.com
- Keywords
- SNS Biotech.
- HQ
- Umeå
Metacurum Biotech Questions
Metacurum Biotech's website is http://www.metacurum.com
Metacurum Biotech's LinkedIn profile is https://se.linkedin.com/company/metacurum-biotech
Metacurum Biotech's industry is
Biotechnology Research
Metacurum Biotech's top competitors are
Buzzard Pharmaceuticals,
Idl Biotech Ab,
Biotech Fluidics,
Sns Biotech,
Giddir Ab,
Biotech Hanse,
Idl Biotech Ab(Publ),
Glucox Biotech,
Kallisti Biotech Ab,
Ai Biotech Sverige.
Metacurum Biotech's categories are Biotechnology Research
Metacurum Biotech's founding year is 2018
